Biomesense Inc.
Chicago, IL
- UEI
- MUZ4XK1Q1L15
- CAGE
- 81U86
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 1452 E 53rd St, Chicago, IL 60615, USA
- Website
- biomesense.com
- Founded
- 2018
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Sbir phase II: development of a novel measurement technology to enable longitudinal multiomic investigations of the… | National Science Foundation | $1,172,080 | |
| Development of a novel biosensor to accelerate investigations of the GUT microbiome - the human GUT microbiome is a… | National Center for Advancing Translational Sciences | $1,794,141 | |
| Development of a novel biosensor to accelerateinvestigations of the GUT microbiome. - project summary / abstract in… | National Center for Advancing Translational Sciences | $883,212 | |
| Sbir phase i: development of a novel biosensor to accelerate investigations of covid-19 and the GUT microbiome. | Division of Industrial Innovation | $255,658 |
About Biomesense Inc.
Biomesense Inc. is a for-profit corporation registered to receive federal awards since February 2018. The company specializes in developing innovative biotechnology platforms and biosensors to advance microbiome research and accelerate investigations related to human health. Biomesense focuses on creating novel measurement technologies that enable large-scale, longitudinal studies of the gut microbiome, with applications in areas such as immunology, metabolism, neurodegenerative disease, cancer, and infectious disease. Their work aims to overcome critical barriers in microbiome research by providing tools for dense, time-longitudinal sampling of participants' gut microbiomes at low cost and with improved patient adherence.
Through federal grant awards, Biomesense Inc. has received funding to develop several cutting-edge technologies. In March 2024, they were awarded a $976,771 cooperative agreement from the National Science Foundation's Technology, Innovation, and Partnerships program to create a platform for measuring and analyzing microbial gene expression in the gut microbiome. This project involves refining RNA capture and storage processes, integrating them into an automated hardware system, and developing analytical methods for the resulting datasets. Previously, in June 2021, the company received an $883,212 project grant from the National Institutes of Health's National Center for Advancing Translational Sciences to develop a novel biosensor for accelerating gut microbiome investigations. This work focused on validating microbial lysis and DNA isolation functions of a prototype biosensor designed for home use. Additionally, in January 2021, Biomesense was awarded a $255,658 SBIR Phase I grant from the National Science Foundation to develop a portable, low-cost biosensor for rapidly detecting SARS-CoV-2 and analyzing gut microbiome composition from patient samples. These projects demonstrate Biomesense's commitment to creating innovative tools that can significantly advance microbiome research and potentially lead to new biomarkers, diagnostics, and therapeutics.
Quick answers
What is Biomesense Inc.'s UEI?
Biomesense Inc.'s Unique Entity ID (UEI) in SAM.gov is MUZ4XK1Q1L15.
What is Biomesense Inc.'s CAGE code?
Biomesense Inc.'s CAGE code is 81U86.
Where is Biomesense Inc. located?
Biomesense Inc.'s physical address in SAM.gov is 1452 E 53rd St, Chicago, IL 60615, USA.
Is Biomesense Inc. registered in SAM.gov?
Yes. Biomesense Inc.'s SAM.gov registration is active through September 2, 2027.
What is Biomesense Inc.'s most recent federal award?
Biomesense Inc.'s most recent federal grant award is Sbir phase II: development of a novel measurement technology to enable longitudinal multiomic investigations of the… (2314685), from National Science Foundation, on March 15, 2024.
On GovTribe
See Biomesense Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors